Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Investor Presentation (November 2019)
26 slides from Ac Immune Sa's investor presentation, Nov 6, 2019
Slide 1: Novel Therapeutics and Diagnostics for Neurodegenerative Diseases
www.acimmune.com © 2019 AC Immune. Not to be used or reproduced without permission. Novel Therapeutics and Diagnostics for Neurodegenerative Diseases Andrea Pfeifer, Ph.D., CEO AC Immune Version November 4
Slide 2: Disclaimer
© 2019 AC Immune. Not to be used or reproduced without permission. 2 NASDAQ: ACIU | KOL Lunch | November 2019 Disclaimer This presentation may contain statements that constitute “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Secu
Slide 3: About AC Immune
© 2019 AC Immune. Not to be used or reproduced without permission. 3 NASDAQ: ACIU | KOL Lunch | November 2019 ▪ Pioneering new ways to treat neurodegenerative diseases associated with misfolded proteins ▪ Listed on Nasdaq since September 2016 (ticker: ACIU) ▪ 71.1 million shares outstanding 1 (free
Slide 4: Investment highlights: AC Immune, a leader in neurodegenerative diseases
© 2019 AC Immune. Not to be used or reproduced without permission. 4 NASDAQ: ACIU | KOL Lunch | November 2019 ▪ Addressing largest market opportunity in healthcare ▪ Pioneering precision medicine in neurodegenerative diseases ▪ CHF 286 million in cash, supports operations through Q3 2023 1 ▪ Increas
Slide 5: "Firsts" reflect ACIU's leadership in NDD
© 2019 AC Immune. Not to be used or reproduced without permission. 5 NASDAQ: ACIU | KOL Lunch | November 2019 “Firsts” reflect ACIU’s leadership in NDD 1 (1) Neurodegenerative diseases; (2) Alzheimer's disease; (3) Progressive supranuclear palsy; (4) First - in - Man; (5) Small molecule Tau - specif
Slide 6: AC Immune's Roadmap to successful therapies for neurodegenerative diseases
AC Immune’s Roadmap to successful therapies for neurodegenerative diseases
Slide 7: Precision medicine is a key driver for effective treatments
© 2019 AC Immune. Not to be used or reproduced without permission. 7 NASDAQ: ACIU | KOL Lunch | November 2019 (1) Reardon S, Nature 2018 ; (2) Pontecorvo MJ, et al ., Brain 2019 ; (3) Gordon BA, et al., Brain 2019 ; (4) Strydom A, et al ., Alzheimers Dement (N Y) 2018 ; (5) Lott IT and Head E., Nat
Slide 8: AC Immune's business strategy
AC Immune’s business strategy
Slide 9: Vision: global leader in precision medicine for neurodegenerative diseases
© 2019 AC Immune. Not to be used or reproduced without permission. 9 NASDAQ: ACIU | KOL Lunch | November 2019 Vision SupraAntigen TM Vaccines and antibodies specific to disease causing conformations Morphomer TM Conformation - sensitive small molecules To become a global leader in precision medicine
Slide 10: Business strategy: 3-pillar approach
© 2019 AC Immune. Not to be used or reproduced without permission. 10 NASDAQ: ACIU | KOL Lunch | November 2019 Precision medicine ultimately creates differentiation Business strategy: 3 - pillar approach Vision Alzheimer’s disease (AD) Non - AD NeuroOrphans Diagnostics Technology platforms Values ▪
Slide 11: Investors and funds from partnerships
© 2019 AC Immune. Not to be used or reproduced without permission. 11 NASDAQ: ACIU | KOL Lunch | November 2019 Investors and funds from partnerships Highly committed institutional investors 1 Five private financing rounds IPO NASDAQ September 2016 Share capital offering of 10 million common shares J
Slide 12: Pipeline and catalysts
Pipeline and catalysts
Slide 13: Driven by proprietary technology platforms for sustained growth
© 2019 AC Immune. Not to be used or reproduced without permission. 13 NASDAQ: ACIU | KOL Lunch | November 2019 Driven by proprietary technology platforms for sustained growth TARGETS PRODUCT CANDIDATE INDICATION DISCOVERY PRECLIN PHASE 1 PHASE 2 PHASE 3 PARTNERS Tau semorinemab (anti - Tau antibody)
Slide 14: Key milestones for 2019
© 2019 AC Immune. Not to be used or reproduced without permission. 14 NASDAQ: ACIU | KOL Lunch | November 2019 Key milestones for 2019 Successful delivery of strategy with multiple near - term catalysts ACI - 24 ACI - 35 a - synuclein TDP - 43 a - synuclein PET tracer Morphomer Tau Phase 1b in DS 2
Slide 15: Focus on Tau
Focus on Tau
Slide 16: AC Immune's molecules target pathological Tau at key points in the disease pathway
© 2019 AC Immune. Not to be used or reproduced without permission. 16 NASDAQ: ACIU | KOL Lunch | November 2019 Affected cell Healthy cell Recipient cell AC Immune’s molecules target pathological Tau at key points in the disease pathway Nucleus Misfolded proteins Normally folded proteins Reverse misf
Slide 17: 2019 Tau pipeline news
© 2019 AC Immune. Not to be used or reproduced without permission. 17 NASDAQ: ACIU | KOL Lunch | November 2019 2019 Tau pipeline news 30m € Milestone payment in connection with initiation of a Phase 2 trial CHF milestone payment clinical trial started to evaluate ACI - 35.030 vaccine Tau PET substud
Slide 18: AC Immune: broadest anti-Tau pipeline with key clinical newsflow
© 2019 AC Immune. Not to be used or reproduced without permission. 18 NASDAQ: ACIU | KOL Lunch | November 2019 Diagnostics and therapies: AC Immune: broadest anti - Tau pipeline with key clinical newsflow funds generated from Tau assets clinical trials diagnostic vaccine antibody small molecule Phas
Slide 19: Anti-Tau antibody Semorinemab – Phase 2 in AD
© 2019 AC Immune. Not to be used or reproduced without permission. 19 NASDAQ: ACIU | KOL Lunch | November 2019 Anti - Tau antibody Semorinemab – Phase 2 in AD 1 (1) Alzheimer’s disease; (2) Healthy volunteers; (3) Mini - mental state exam; (4) Clinical Dementia Rating - Global Score; (5) Clin ical D
Slide 20: Preclinical programs with newsflow in Q3
Preclinical programs with newsflow in Q3
Slide 21: Anti-a-synuclein antibody – Discovery in PD
© 2019 AC Immune. Not to be used or reproduced without permission. 21 NASDAQ: ACIU | KOL Lunch | November 2019 Target Misfolded, aggregated a - synuclein (a - syn) Target characteristics ▪ Pathological a - syn aggregates and forms oligomers and fibrils ▪ Aggregation and spreading of misfolded a - sy
Slide 22: Anti-TDP-43 antibodies – Discovery Phase
© 2019 AC Immune. Not to be used or reproduced without permission. 22 NASDAQ: ACIU | KOL Lunch | November 2019 Target Aggregated TDP - 43 1 Target characteristics ▪ TDP - 43 is a RNA/DNA binding protein involved in RNA metabolism ▪ Aggregated TDP - 43 loses its physiological function and the extrace
Slide 23: Strategic outlook
Strategic outlook
Slide 24: Strategy for value creation
© 2019 AC Immune. Not to be used or reproduced without permission. 24 NASDAQ: ACIU | KOL Lunch | November 2019 Strategy for value creation 3. INVEST to further build leadership in neurodegenerative diseases ▪ Execute in line with our “Roadmap” ▪ Focus on Tau and new targets in neuroinflammation 1 .
Slide 25: Milestone highlights H1 2020
© 2019 AC Immune. Not to be used or reproduced without permission. 25 NASDAQ: ACIU | KOL Lunch | November 2019 Milestone highlights H1 2020 Identification of first NLPR3 - ASC inflammasome inhibitor with in vivo activity Semorinemab anti - Tau antibody Phase 2 primary completion estimated in prodrom
Slide 26: We continue to shape the future of neurodegeneration
© 2019 AC Immune. Not to be used or reproduced without permission. 26 NASDAQ: ACIU | KOL Lunch | November 2019 We continue to shape the future of neurodegeneration by discovering and developing breakthrough therapies through pioneering science and precision medicine AC Immune